You know that an idea has become mainstream when you hear people discuss it in casual conversation. That's something I've seen when it comes to glucagon-like peptide-1 (GLP-1) drugs.
What started out as a treatment for type-2 diabetes has become a mainstream solution for millions of Americans who struggle with obesity. And increasingly, it's becoming a weight loss solution for individuals who aren't obese but have the means to pay the hefty price tag.
Not surprisingly, investors have seen the stocks of companies that offer GLP-1 drugs soar. In fact, like artificial intelligence (AI), any company that is floating the idea of a GLP-1 drug was getting a lift.
But even as the number of companies throwing their hat in the GLP-1 ring expands, the winners are becoming more defined. In this special presentation, we're looking at seven stocks to consider if you're looking to get a piece of this emerging sector.
Click the "Continue to Slide #1" button to view the first company.
